Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, has entered into a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC® in Israel. GelrinC is Regentis' proprietary implant for repairing damaged knee cartilage and has received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States.
The agreement is significant because it represents a concrete step in Regentis' commercialization strategy for GelrinC, leveraging AMI's established relationships with orthopedic surgeons, hospitals, and clinics to support the product's commercial introduction. The deal includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in 2027. This provides a clear timeline for potential revenue generation and signals confidence in the product's market acceptance.
Moreover, the companies will collaborate to establish reimbursement coverage for GelrinC with Israel's leading health maintenance organizations and promote adoption among orthopedic surgeons treating patients with focal cartilage defects. Until reimbursement coverage is established, patients may be able to access the implant through private health insurance. This reimbursement effort is critical for ensuring patient access and driving adoption, as it addresses a key barrier to uptake.
The agreement also supports Regentis' broader commercialization efforts in Europe and Israel as the company continues advancing its pivotal Phase 3 clinical program in the United States. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. The Israel agreement thus serves as a potential springboard for further market expansions and validates the technology platform.
Regentis Biomaterials is dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate cartilage in a controlled and synchronous process.
For investors, this announcement highlights progress in Regentis' commercialization plan and provides a potential revenue stream starting in 2027. The exclusive nature of the agreement and the minimum purchase requirements underscore AMI's commitment to the product. As Regentis continues to advance its U.S. clinical program, the Israel agreement may serve as a proof point for the product's viability in other markets. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT.
BioMedWire is a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries, along with article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
